Pathway Bio

Pathway Bio is a precision oncology company developing a functional platform to predict treatment response in individual cancer patients.

The platform combines multiomic tumour profiling, AI-driven modelling, and ex vivo microcancer technology to screen therapies against a biological avatar of the patient's own tumour within six to ten days, before treatment begins.

Validation data covering 400 patients has been developed in collaboration with Mayo Clinic.